Estudio de dosis flexibles de paliperidona ER en pacientes con esquizofrenia previamente tratados sin efectividad con otros antipsicóticos*
Tài liệu tham khảo
American Psychiatric Association (APA), 1994
Saha, 2005, A systematic review of the prevalence of schizophrenia, PLoS Med, 2, e141, 10.1371/journal.pmed.0020141
McDonagh, 2010
Lehman, 2004, APA practice guidelines: Schizophrenia, Am J Psychiatry, 161, S1
Melnik, 2010, Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews, Sao Paulo Med J, 128, 141, 10.1590/S1516-31802010000300007
Marder, 2006, Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness, J Clin Psychiatry, 67, e03, 10.4088/JCP.0706e03
von Hausswolff-Juhlin, 2009, Schizophrenia and physical health problems, Acta Psychiatr Scand, 15, 10.1111/j.1600-0447.2008.01309.x
Bobes, 2005, Quality of life measures in schizophrenia, Eur Psychiatry, S313, 10.1016/S0924-9338(05)80182-8
Stroup, 2009, Results of phase 3 of the CATIE schizophrenia trial, Schizophr Res, 107, 1, 10.1016/j.schres.2008.10.011
Jones, 2010, Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia, Int J Clin Pharmacol Ther, 48, 383, 10.5414/CPP48383
Llorca, 2005, Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation, Encephale, 31, 235, 10.1016/S0013-7006(05)82390-5
Newcomer, 2005, Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review, CNS Drugs, 19, S1
Janicak, 2007, Paliperidone ER: a review of the clinical trial data, Neuropsychiatr Dis Treat, 3, 869, 10.2147/NDT.S1365
Lautenschlager, 2008, Paliperidone-ER: first atypical antipsychotic with oral extended release formulation, Expert Rev Neurother, 8, 193, 10.1586/14737175.8.2.193
Marino, 2008, Paliperidone extended-release for the treatment of schizophrenia, Pharmacotherapy, 28, 1283, 10.1592/phco.28.10.1283
Fowler, 2008, Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia, Clin Ther, 30, 231, 10.1016/j.clinthera.2008.02.011
Conley, 2006, Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form, Curr Med Res Opin, 22, 1879, 10.1185/030079906X132613
Liu, 2011, Osmotic-controlled release oral delivery system (OROS) paliperidone-related pruritic rash, J Clin Psychopharmacol, 31, 525, 10.1097/JCP.0b013e318222b958
Kane, 2007, Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial, Schizophr Res, 90, 147, 10.1016/j.schres.2006.09.012
Marder, 2007, Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study, Biol Psychiatry, 62, 1363, 10.1016/j.biopsych.2007.01.017
Meltzer, 2008, Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies, J Clin Psychiatry, 69, 817, 10.4088/JCP.v69n0515
Emsley, 2008, Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies, Int Clin Psychopharmacol, 23, 343, 10.1097/YIC.0b013e328314e1f3
Canuso, 2008, Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone, Int Clin Psychopharmacol, 23, 209, 10.1097/YIC.0b013e3282fce651
Tzimos, 2008, Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension, Am J Geriatr Psychiatry, 16, 31, 10.1097/JGP.0b013e31815a3e7a
Morosini, 2000, Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning, Acta Psychiatr Scand, 101, 323, 10.1111/j.1600-0447.2000.tb10933.x
Tessier C, Hoeben D2, Lahaye M, et al. A Flexible-dose Study of paliperidone er in non-acute patients with schizophrenia previously unsuccessfully treated with oral quetiapine. Presented at the 27th Collegium Internationale Neuro-Psychopharmacologicum (CINP) World Congress, 6-10 June 2010, Hong Kong, China.
Schreiner A, Dilbaz N, Kotler M, et al. Paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with oral olanzapine. Presented at the XXVII CINP Biennial International World Congress 2010, Hong Kong, 6-10 June, 2010
Schreiner A, Hoeben D, Lahaye M, et al. A flexible-dose study of paliperidone ER in non-acute patients with schizophrenia previously unsuccessfully treated with aripiprazole. Presented at the XXVII CINP Biennial International World Congress 2010, Hong Kong, 6-10 June, 2010.
Schreiner A, Hoeben D, Tessier C, et al. Tolerability and treatment responses in patients with recently diagnosed vs chronic schizophrenia treated with paliperidone ER. Presented at the 19th European Congress of Psychiatry (EPA), 12-15 March 2011, Vienna, Austria.
Tessier C, Franco MA, Millet B, et al. Functioning in patients with recently diagnosed vs chronic schizophrenia treated with paliperidone ER. Presented at the 16th Biennial Winter Workshop in Psychoses (WWP), 30 January-2 February 2011, Innsbruck, Austria.